CoDa Therapeutics Achieves Positive Phase 2 Efficacy of NEXAGON® in Chronic Venous Leg Ulcers
For More Information, please contact:
CoDa Therapeutics Inc.
Bradford Duft, President and CEO (email@example.com)
David Pool, CFO (firstname.lastname@example.org)
The Ruth Group (on behalf of CoDa Therapeutics in the US)
Sara Pellegrino – Investors (646-536-7002 / email@example.com)
Jason Rando – Media (646-536-7025 / firstname.lastname@example.org)